DOCSLIB.ORG

Colorectal Cancer Screening and Risk Assessment Workflow Documentation Guide for Health Center Nextgen Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Colorectal Cancer Screening and Risk Assessment Workflow Documentation Guide for Health Center NextGen Users Colorectal Cancer Screening and Risk Assessment Workflow and Documentation Guide for Health Center NextGen Users TABLE OF CONTENTS Introduction and Purpose .................................................................................................. 2 Background .......................................................................................................................... 2 Sections of this Guide ......................................................................................................... 3 Section I: Current NextGen Documents Supporting CRC Screening ............................ 3 • Overview • Ordering a FOBT or FIT • Documenting FOBT/FIT Results • Ordering a Colonoscopy or Sigmoidoscopy • Documenting Colonoscopy Results • Documenting a Historical Colonoscopy • Documenting a Colectomy or Colorectal Cancer Section II: Additional Guidance on Using NextGen for CRC Screening ........................ 4 • Assessing Need for Colorectal Cancer Screening • Assessing and Defining Individual Patient Risk • Documenting Family History • Generating Screening Reports • Tracking, Follow-up & Closing the Loop • Refusal • Patient Education • Patient Outreach • Additional Tools Section III: Alternate Health Center Examples of CRC Screening Strategies ............... 10 • Harbor Health Services Case Study © National Association of Community Health Centers, all rights reserved, 1.21.19 1 Introduction and Purpose: This Guide provides focused documentation to assist users of NextGen software to improve the process of assessing, documenting, tracking, and following up on colorectal cancer screening. The Guide gives particular attention to assessment of personal and family risk and the tracking and follow-up of screening results that are not addressed in the standard NextGen guidance documents. This work aims to improve health center compliance with HRSA Uniform Data Systems (UDS) colorectal cancer screening (CRCS) through the development and implementation of workflows that produce accurate and reliable structured data and enable proactive outreach and timely follow-up with patients due for CRCS or follow-up testing. This optimization enables health centers to harness broader evidence-based strategies to improve CRCS compliance, and ultimately, health outcomes. Background: Extensive documentation exists regarding evidenced-based practices and expert-endorsed recommendations for increasing colorectal cancer screening, including the guide on How to Increase Colorectal Cancer Screening Rates in Practice: A Primary Care Clinician’s Evidence-Based Toolbox1 and Steps for Increasing Colorectal Cancer Screening Rates: A Manual for Community Health Centers2. Yet, applying these recommendations within the real-world electronic health records (EHRs) in use by providers remains a challenge. Previous work by HealthEfficient (formerly Health Center Controlled Network of New York) and the National Association of Community Health Centers, Inc. (NACHC), under funding from the American Cancer Society (ACS), created one such guide for health center users of eClinicalWorks. This Guide now extends this work to NextGen, an electronic health record frequently used by health centers today. It builds upon NextGen’s Colorectal Cancer Screening Measure UDS Workflow3 by providing additional guidance for documenting risk in the NextGen product, including application of the American Cancer Society’s updated screening algorithm that incorporates the latest evidence-based guidelines for colorectal cancer screening, follow-up, and documentation of screening results. This Guide was initially developed by Harbor Health Services in collaboration with the Massachusetts League of Community Health Centers and NACHC, with support from the ACS. Additional review and comment was provided by El Rio Community Health Center. This guide was developed for NextGen Version; 5.8.1 KBM 8.3.4. The guidance outlined here recognizes that documentation of colorectal cancer screening (CRCS) typically takes place within the context of a primary care visit. This requires that CRCS documentation guidance consider screening as part of the overall patient visit process. Critical to this exercise is documenting CRCS using structured fields within the NextGen product. Structured data refers to any data that reside in a fixed field within the patient record used for relational databases and spreadsheets. Structured data are dependent on how the data is recorded, stored, processed and accessed. This includes defining what fields of data will be stored and how that data will be stored (e.g., whether numeric, alphabetic, name, date, or address), as well as how the data will be input into the EHR (e.g., number of characters, certain fields, and/or EHR templates). NextGen structured data fields are referenced throughout the Guide using the named area of the EHR. Screenshots have been omitted pending NextGen approval. 1 American Cancer Society. Sarfaty, M (2008). How to Increase Colorectal Cancer Screening Rates in Practice: A Primary Care Clinician’s Evidence-Based Toolbox and Guide. 2008. Retrieved from: https://www.cancer.org/content/dam/cancer-org/cancer-control/en/reports/how-to-increase-preventive- screening-rates-in-practice.pdf 2 American Cancer Society. Syl, M., Sarfaty, M. (2016). Steps for Increasing Colorectal Cancer Screening Rates: A Manual for Community Health Centers. Atlanta, GA: American Cancer Society. Retrieved from: http://nccrt.org/wp-content/uploads/0305.60-Colorectal-Cancer-Manual_FULFILL.pdf 3 NextGen Healthcare. Colorectal Cancer Screening Measure UDS Workflow. 2016. © National Association of Community Health Centers, all rights reserved, 1.21.19 2 Sections of this Guide The design of this Guide is structured to provide information on the use of NextGen as a tool to increase colorectal cancer screening as well as offer additional examples of strategies and tools in use by health centers to maximize screening efforts. The Guide is divided into three sections: Section I: Current NextGen Documents Supporting CRC Screening NextGen® Ambulatory Products: Colorectal Cancer Screening Measure UDS Workflow V5.8 UD2 Section II: Additional Guidance on Using NextGen for CRC Screening Additional NextGen-Supported Patient Visit Workflows that Incorporate CRC Screening Section III: Alternate Health Center Examples of CRC Screening Strategies Alternate Patient Visit Workflows that Incorporate Colorectal Cancer Screening Section I: NextGen® Ambulatory Products: Colorectal Cancer Screening Measure UDS Workflow, Version 5.8 UD2 NextGen has several existing ambulatory products to support colorectal cancer screenings. Refer to NextGen® Ambulatory Products: Colorectal Cancer Screening Measure UDS Workflow, Version 5.8 UD2 to access the following workflows. • Ordering a FOBT or FIT • Documenting FOBT/FIT Results • Ordering a Colonoscopy or Sigmoidoscopy • Documenting a Colonoscopy Results • Documenting a Historical Colonoscopy • Documenting a Colectomy or Colorectal Cancer © National Association of Community Health Centers, all rights reserved, 1.21.19 3 Section II: Additional Guidance on Using NextGen for CRC Screening Colorectal Cancer Screening Colon Cancer is one of the few cancers that can be prevented with proper screening. The United States Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer beginning at age 50 years and continuing until age 75 years4. A joint guideline by the American Cancer Society, US Multi-Society Task Force on Colorectal Cancer, and American College of Radiology recommends that individuals with a personal or family history of colorectal cancer or polyps or personal history of chronic inflammatory bowel disease undergo more frequent screening5. The American Cancer Society (ACS) recently released a CRCS algorithm that reflects this joint guidance (Figure 1). ACS also released a CRCS screening algorithm that reflects its recently updated recommendation to begin colorectal cancer screening at age 45 (Figure 2). As part of federal reporting requirements, health centers are required to report on the percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer. These Uniform Data System (UDS) requirements define appropriate screening as any one of the following6: • Fecal occult blood test, which includes guaic fecal occult blood test (gFOBT) and the immunochemical-based fecal occult blood test (iFOBT), during the measurement period. • Fecal immunochemical test (FIT)-deoxyribonucleic acid (DNA) during the measurement period or the 2 years prior to the measurement period. • Flexible sigmoidoscopy during the measurement period or the 4 years prior to the measurement period. • Computerized tomography (CT) colonography during the measurement period or the 4 years prior to the measurement period. • Colonoscopy during the measurement period or the 9 years prior to the measurement period. • Excluded are patients with a diagnosis of colorectal cancer or a history of total colectomy and patients in hospice care during the measurement period. Ass 4 U.S. Preventive Services Task Force. June 2017. Final Recommendation Statement: Colorectal Cancer: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/colorectal-cancer-screening2. 5 Levin, B., Lieberman, D.A., McFarland, B., Smith, R.A., Brooks, D., Andrews, K.S., et. al. 2008. Screening and Surveillance for
Recommended publications
  • Preventive Health Care

    Preventive Health Care

    PREVENTIVE HEALTH CARE DANA BARTLETT, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT Screening is an effective method for detecting and preventing acute and chronic diseases. In the United States healthcare tends to be provided after someone has become unwell and medical attention is sought. Poor health habits play a large part in the pathogenesis and progression of many common, chronic diseases. Conversely, healthy habits are very effective at preventing many diseases. The common causes of chronic disease and prevention are discussed with a primary focus on the role of health professionals to provide preventive healthcare and to educate patients to recognize risk factors and to avoid a chronic disease. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities.
  • Colorectal Cancer Screening Algorithm

    Colorectal Cancer Screening Algorithm

    Colorectal Cancer Screening Page 1 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. This algorithm is not intended for individuals with a personal history of colorectal cancer 1. Note: Screening for adults age 76 to 85 years old should be evaluated on an individual basis by their health care provider to assess the risks and benefits of screen ing. Colorectal cancer screening is not recommended over age 85 years. TABLE OF CONTENTS Average Risk …………..………………...……………………..………………………………...Page 2 Increased Risk ………………………...…………………...………….………………………….Page 3 High Risk ………………………………………………………………………………………....Page 4 Suggested Readings …………………………………...……...………………………………….Page 5 Development Credits ………………………………………………….........................................Page 6 1 See the Colon or Rectal Cancer Treatment or Survivorship algorithms for the management of individuals with a personal history of colorectal cancer Department of Clinical Effectiveness V9 Approved by the Executive Committee of the Medical Staff on 09/21/2021 Colorectal Cancer Screening – Average Risk Page 2 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary

    Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary

    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
  • American Cancer Society Flufobt Program Implementation Guide for Primary Care Practices

    American Cancer Society Flufobt Program Implementation Guide for Primary Care Practices

    Health Care Solutions From the American Cancer Society American Cancer Society FluFOBT Program Implementation Guide for Primary Care Practices EIGHTY BY 2018 Reaching 80% screened for colorectal cancer by 2018 Table of Contents Introduction ................................................................................................................................. 2 Background Information and Education .................................................................................... 3 Why Have a FluFOBT Program? .................................................................................................. 4 Colorectal Cancer Screening Eligibility ...................................................................................... 5 Colorectal Cancer Screening Recommendations ....................................................................... 6 Patient Education ......................................................................................................................... 8 How to Set Up Your FluFOBT Program .................................................................................... 10 Staff Training for Your FluFOBT Program ................................................................................ 16 Summary ..................................................................................................................................... 19 Appendix A: FluFOBT Components and Logic Model ............................................................ 20 Appendix B: Colorectal Cancer Screening Recommendations
  • (NCCN Guidelines®) Colorectal Cancer Screening

    (NCCN Guidelines®) Colorectal Cancer Screening

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colorectal Cancer Screening Version 2.2017 — November 14, 2017 NCCN.org Continue Version 2.2017, 11/14/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® NCCN Guidelines Version 2.2017 Panel Members NCCN Guidelines Index Table of Contents Colorectal Cancer Screening Discussion * Dawn Provenzale, MD, MS/Chair ¤ Þ Michael J. Hall, MD, MS † ∆ Robert J. Mayer, MD † Þ Duke Cancer Institute Fox Chase Cancer Center Dana-Farber/Brigham and Women’s Cancer Center * Samir Gupta, MD/Vice-chair ¤ Amy L. Halverson, MD ¶ UC San Diego Moores Cancer Center Robert H. Lurie Comprehensive Cancer Reid M. Ness, MD, MPH ¤ Center of Northwestern University Vanderbilt-Ingram Cancer Center Dennis J. Ahnen, MD ¤ University of Colorado Cancer Center Stanley R. Hamilton, MD ≠ Scott E. Regenbogen, MD ¶ The University of Texas University of Michigan Travis Bray, PhD ¥ MD Anderson Cancer Center Comprehensive Cancer Center Hereditary Colon Cancer Foundation Heather Hampel, MS, CGC ∆ Niloy Jewel Samadder, MD ¤ Daniel C. Chung, MD ¤ ∆ The Ohio State University Comprehensive Huntsman Cancer Institute at the Massachusetts General Hospital Cancer Center - James Cancer Hospital University of Utah Cancer Center and Solove Research Institute Moshe Shike, MD ¤ Þ Gregory Cooper, MD ¤ Jason B. Klapman, MD ¤ Memorial Sloan Kettering Cancer Center Case Comprehensive Cancer Center/ Moffitt Cancer Center University Hospitals Seidman Cancer Thomas P. Slavin Jr, MD ∆ Center and Cleveland Clinic Taussig David W. Larson, MD, MBA¶ City of Hope Comprehensive Cancer Institute Mayo Clinic Cancer Center Cancer Center Dayna S.
  • High Quality Fecal Occult Blood Testing (FOBT) for CRC Screening: Evidence and Recommendations

    High Quality Fecal Occult Blood Testing (FOBT) for CRC Screening: Evidence and Recommendations

    High Quality Fecal Occult Blood Testing (FOBT) for CRC Screening: Evidence and Recommendations Rationale for use of FOBT High sensitivity fecal occult blood testing (FOBT) is one of the colorectal cancer screening methods recommended in guidelines from the American Cancer Society, the US Preventive Services Taskforce, and every other major medical organization. In spite of this widespread endorsement, primary care clinicians often express conviction that colonoscopy is the “gold standard” test for colorectal cancer screening and that the use of FOBT represents sub-standard care. These beliefs persist in spite of well-documented shortcomings of endoscopy (missed adenomas and cancers, higher complication rates and higher one-time costs than other screening methodologies), and the fact that access to endoscopy is limited or non- existent for a significant proportion of the U.S. population. Many clinicians are also unaware that randomized controlled trials of FOBT screening have demonstrated decreases in colorectal cancer incidence and mortality, and modeling studies suggest that the years of life saved through a high quality FOBT screening program are essentially the same as with a high quality colonoscopy based screening programs. Recent advances in stool blood screening include the emergence of new tests and improved understanding of the impact of quality factors on testing outcomes. This document provides state-of-the-science information about high quality stool testing. Types of Fecal Occult Blood Tests Two main types of FOBT are available – guaiac and immunochemical. Both types of FOBT have been shown to have reasonably high detection rates for colon and rectal cancers; adenoma detection rates are appreciably lower.
  • Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: an Update for the U.S

    Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: an Update for the U.S

    Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force Linda L. Humphrey, MD, MPH; Steven Teutsch, MD, MPH; Mark S. Johnson, MD, MPH Screening for lung cancer is not currently increasing in epidemic proportions,3,4 with an recommended by any major medical professional estimated 1 million deaths in the year 2000.5 organization. The U.S. Preventive Services Task Although there are other important risk factors Force (USPSTF) gave lung cancer screening a “D” for lung cancer,3,6–10 cigarette smoking is the major recommendation in both 1985 and 1996, meaning risk factor; approximately 87% of all lung, that there were fair-quality data to recommend bronchial, and tracheal cancer are attributed to against screening for lung cancer1 based largely on 3 smoking.3 Consequently, the most important public negative trials conducted in the United States in the health intervention that could reduce lung cancer 1970s. Since the last Task Force review, several new incidence and deaths is changing smoking habits. studies of lung cancer screening have been reported, Unfortunately, although overall prevalence rates of and greater attention has been directed toward the smoking in the United States have decreased over limitations of existing literature. This review was the past 2 decades, the prevalence of current adult conducted to aid the current USPSTF in updating smokers remains high at 24%.10,11 In the clinical its lung cancer screening recommendation. setting,
  • Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S

    Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S

    Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD, MACG1, C. Richard Boland, MD2, Jason A. Dominitz, MD, MHS3, Francis M. Giardiello, MD4, David A. Johnson, MD, MACG5, Tonya Kaltenbach, MD, FACG6, Theodore R. Levin, MD, FACG7, David Lieberman, MD, FACG8 and Douglas J. Robertson, MD, MPH9 1Indiana University School of Medicine, Indianapolis, Indiana, USA; 2University of California San Diego, San Diego, California, USA; 3VA Puget Sound Health Care System, University of Washington, Seattle, Washington, USA; 4Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5Eastern Virginia Medical School, Norfolk, Virginia, USA; 6San Francisco Veterans Affairs Medical Center, San Francisco, California, USA; 7Kaiser Permanente Medical Center, Walnut Creek, California, USA; 8Oregon Health and Science University, Portland, Oregon, USA; 9VA Medical Center, White River Junction, Vermont, and Geisel School of Medicine at Dartmouth, Hanover, New Hampshire Am J Gastroenterol advance online publication 6 June 2017; doi: 10.1038/ajg.2017.174 Abstract This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi- Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy.
  • Prostate Cancer Screening NATIONAL GUIDELINE SUMMARY the Guideline Was Developed Using an Evidence-Based Methodology

    Prostate Cancer Screening NATIONAL GUIDELINE SUMMARY the Guideline Was Developed Using an Evidence-Based Methodology

    Prostate Cancer Screening NATIONAL GUIDELINE SUMMARY The guideline was developed using an evidence-based methodology. This guideline summary is intended to guide health care professionals with prostate cancer screening in asymptomatic adult men. It does not apply to men who have signs or symptoms of prostate disease, or in whom a diagnosis has already been made. PROSTATE CANCER SCREENING AND Men with an elevated PSA have approximately a 70% chance of having a prostate biopsy that is negative for SHARED DECISION-MAKING cancer. • For average risk men, offer prostate cancer screening If a cancer is detected, it may or may not ever become with prostate-specifi c antigen (PSA) testing and digital clinically signifi cant3 in a man’s lifetime. rectal examination (DRE) in the context of a shared If diagnosed, the grade and stage of the cancer determines decision-making approach starting at age 50. the likely effectiveness of treatment. Potential benefi ts • For higher risk men (i.e., black/African-American of prostate cancer treatments may include increased life descent, family history of at least one fi rst degree span, and reduction in morbidity from locally advanced and relative with prostate cancer), offer prostate cancer metastatic disease. Prostate cancer treatments may also screening with PSA and DRE in the context of a shared have potential complications. Some men with prostate decision-making approach starting at age 40. cancer may elect not to be treated after discussion with their urologist. • Prostate cancer screening is not recommended for men age 75 or older. IF SCREENING IS REQUESTED • In the shared decision-making approach, include • For men who elect to participate in prostate cancer information regarding the potential benefi ts and risks screening: of undergoing screening for prostate cancer.
  • Colorectal Cancer Screening

    Colorectal Cancer Screening

    | PATIENT RESOURCE | Colorectal Cancer Screening You have choices when it comes to colorectal cancer screening The best test is the one that gets done * Colonoscopy Multi-target Stool DNA Test* FIT/FOBT (visual exam) (Cologuard®) (fecal immunochemical test/ fecal occult blood test) Uses a scope to look for and Finds abnormal DNA and Detects blood in How does it work? remove abnormal growths blood in the stool sample the stool sample in the colon/rectum Who is it for? Adults starting at age 45 Adults starting at age 45 Adults starting at age 45 How often? Every 10 years† Every 3 years Once a year Moderately invasive, done at Yes, done at home Yes, done at home Non-invasive? hospital or doctor office Yes, however preps have greatly No No/Yes‡ Prep required? improved in recent years Prep: night before Time to collect and mail sample Time to collect and mail sample Time it takes? Procedure: next day Covered?§ Covered by most insurers Covered by most insurers Covered by most insurers Abnormal growths (polyps) If positive, a follow-up If positive, a follow-up removed during colonoscopy Next steps colonoscopy is needed colonoscopy is needed » for evaluation *All positive results on non-colonoscopy screening tests should be followed up with a timely colonoscopy. †For adults at high risk, testing may be more frequent and should be discussed with your health care provider. ‡FIT does not require changes to diet or medication. FOBT requires changes to diet or medication. §Insurance coverage can vary; only your insurer can confirm how colon cancer screening would be covered under your insurance policy.
  • Preventive Health Care

    Preventive Health Care

    PREVENTIVE HEALTH CARE Understanding what’s covered What is preventive care? What’s not considered preventive care? Preventive care is a specific group of services Once you have a symptom or your health care provider recommended when you don’t have any symptoms diagnoses a health issue, additional tests are not and haven’t been diagnosed with a related health considered preventive care. Also, you may receive issue. It includes your periodic wellness exam other medically appropriate services during a periodic (check-up) and specific tests, certain health wellness exam that are not considered preventive. screenings, and most immunizations. Most of these These services may be covered under your plan’s services typically can take place during the same visit. medical benefits, not your preventive care benefits. You and your health care provider will decide what This means you may be responsible for paying a preventive services are right for you, based on your: share or all of the cost. This may include your plan’s › Age deductible, copay or coinsurance amounts, depending on your plan. › Gender › Personal health history Which preventive services are covered? › Current health Many plans cover preventive care at no additional cost to you when you use a health care provider Why do I need preventive care? in your plan’s network. Use the provider directory on myCigna.com Preventive care can help you detect problems at early for a list of in-network health care stages, when they may be easier to treat. It can also providers and facilities. help you prevent certain illnesses and health conditions See the charts on the following pages for the services from happening.
  • Colorectal Cancer Tests Save Lives: the Best Test Is the Test That Gets Done

    Colorectal Cancer Tests Save Lives: the Best Test Is the Test That Gets Done

    November 2013 Colorectal Cancer Tests Save Lives The best test is the test that gets done Colorectal cancer (CRC) is the second leading cancer killer of men and women in the US, following lung cancer. The US Preventive Services Task Force (USPSTF) recommends three CRC screening tests that are effective 90% at saving lives: colonoscopy, stool tests (guaiac fecal occult About 90% of people live 5 or more blood test-FOBT or fecal immunochemical test-FIT), and years when their colorectal cancer sigmoidoscopy (now seldom done). is found early through testing. Testing saves lives, but only if people get tested. Studies show that people who are able to pick the test they prefer are more likely to actually get the test done. Increasing the use of all recommended colorectal cancer tests can save 1 in 3 more lives and is cost-effective. To increase testing, doctors, nurses, and health About 1 in 3 adults systems can: (23 million) between 50 and ◊ Offer all recommended test options with advice about each. 75 years old is not getting tested as recommended. ◊ Match patients with the test they are most likely to complete. ◊ Work with public health professionals to: ■ Get more adults tested by hiring and training “patient navigators,” who are staff that help people 1 in 10 learn about, get scheduled for, and get procedures done like colonoscopy. 10% of adults who got tested for colorectal cancer ■ Create ways to make it easier for people to get used an effective at-home FOBT/FIT kits in places other than a doctor’s office, stool test.